Teri Greiling, MD
Dermatology · Portland, ORNPI 1609168913
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,125 of the $8,044 with a category attached, or 63.7%. Sanofi accounts for 63.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $5,164 and has fallen 97.1% since, to $150 in 2025.
Across 9 payments — averaging $893.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$5K
- Novartis$2K
- Johnson & Johnson$150
- Bristol Myers Squibb$137
- Boehringer Ingelheim$116
- Lilly USA, LLC$64
- plus $52 from 2 others
Across 98 payments — averaging $10,115 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$328K
- Amgen$200K
- Eli Lilly$180K
- Regeneron$146K
- Lilly USA, LLC$132K
- Biogen$4K
- plus $287 from 1 others
What the payments were for
- Consulting fees$2,40030%
- Speaking & faculty fees$5,12564%
- Food & beverage$5196%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $5,125 |
| Novartis | 1 | $2,400 |
| Johnson & Johnson | 1 | $150 |
| Bristol Myers Squibb | 1 | $137 |
| Boehringer Ingelheim | 1 | $116 |
| Lilly USA, LLC | 2 | $64 |
| Janssen Scientific Affairs, LLC | 1 | $39 |
| Janssen Research & Development, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,044 in reported general payments places this provider in the 80th percentile of 175 dermatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 14 | $269,789 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 20 | $230,015 |
| Dupixent PenDupilumab | 30 | $115,013 |
| Dupixent SyringeDupilumab | 17 | $66,506 |
| Tacrolimus | 44 | $5,448 |
| Clobetasol Propionate | 77 | $4,039 |
| Mycophenolate Mofetil | 24 | $3,952 |
| Acitretin | 11 | $3,225 |
| Dapsone | 34 | $2,703 |
| Betamethasone Dipropionate | 43 | $2,620 |
| Doxycycline Monohydrate | 34 | $2,444 |
| Fluorouracil | 22 | $1,263 |
| MethotrexateMethotrexate Sodium | 50 | $1,093 |
| Triamcinolone Acetonide | 60 | $1,044 |
| Metronidazole | 21 | $878 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Portland
- Andrew BlauveltPortland$1.8M
- Benjamin EhstPortland$1.5M
- Jason HawkesPortland$1.5M
- Eric SimpsonPortland$1.4M
- Alex Ortega LoayzaPortland$122K
- Omar QutubPortland$107K
- Paul HaunPortland$85K
- Kathryn SchwarzenbergerPortland$34K
- Jon HanifinPortland$25K
- Phoebe RichPortland$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.